Hepatitis C virus (HCV) drug susceptibility testing is a specialized laboratory service that evaluates the sensitivity of HCV to direct-acting antiviral agents (DAAs) by detecting resistance-associated substitutions and measuring phenotypic susceptibility. This testing plays a critical role in guiding treatment decisions, supporting retreatment strategies after therapy failure, and advancing antiviral drug development.
Technical Overview
Hepatitis C virus drug susceptibility testing refers to a set of genotypic and phenotypic assays designed to determine how sensitive a patient's HCV population is to antiviral drugs, particularly direct-acting antivirals (DAAs). Since the introduction of DAAs targeting the NS3/4A protease, the NS5A protein, and the NS5B RNA-dependent RNA polymerase, cure rates for chronic hepatitis C have exceeded 95%. However, resistance-associated substitutions (RASs) can emerge during treatment, especially in patients with prior DAA failure, cirrhosis, or difficult-to-treat genotypes, potentially compromising subsequent therapy. Susceptibility testing combines sequence-based resistance detection with cell-culture-based phenotypic assays to quantify the fold-change in drug potency (EC50 shift) caused by specific viral variants, providing clinicians and researchers with actionable data for optimized therapeutic management.
Testing Samples
Plasma or Serum
EDTA plasma or serum containing detectable HCV RNA is the primary specimen type. A minimum viral load of approximately 1,000 IU/mL is generally required for reliable amplification of the NS3, NS5A, and NS5B target regions.
Peripheral Blood Mononuclear Cells (PBMCs)
PBMC specimens may be collected when investigating extra-hepatic viral reservoirs or when paired analysis of intracellular and circulating viral quasispecies is required.
Cell Culture-Derived Virus Stocks
For research and drug development programs, laboratory strains (e.g., HCVcc JFH-1 derivatives), replicon cell lines, or patient-derived chimeric viruses propagated in vitro can be submitted for susceptibility profiling.
Clinical Isolates and Archived RNA
Stored RNA extracts, cDNA libraries, or sequenced amplicons from prior resistance testing may be accepted for comparative longitudinal analysis of viral evolution before and after antiviral exposure.
Testing Items
Susceptibility testing covers the three major DAA drug targets and the corresponding resistance pathways:
- NS3/4A protease inhibitor susceptibility, including detection of key substitutions such as Q80K, R155K, A156T/V, and D168A/E/V, relevant to agents such as glecaprevir, voxilaprevir, and simeprevir.
- NS5A inhibitor susceptibility, covering substitutions such as M28V, L31M/V, Q54H, Y93H/N, and complex resistance patterns affecting ledipasvir, daclatasvir, velpatasvir, and pibrentasvir.
- NS5B polymerase inhibitor susceptibility, including S282T, L159F, and C316N variants that may influence nucleoside and non-nucleoside inhibitor efficacy, including sofosbuvir.
- Phenotypic EC50 and EC90 determination for selected DAAs using replicon or infectious virus systems, with results reported as fold-change relative to a wild-type reference strain.
- Full-genome or target-region next-generation sequencing (NGS) to quantify minor resistant variants present at frequencies as low as 1%.
- Replication capacity assessment of mutant replicons to evaluate viral fitness in the presence and absence of drug pressure.
Testing Methods
Genotypic Resistance Testing
Viral RNA is extracted from patient specimens, reverse-transcribed, and amplified by RT-PCR across the NS3, NS5A, and NS5B coding regions. Population-based Sanger sequencing identifies dominant resistance-associated substitutions, while deep NGS platforms (Illumina or Ion Torrent) resolve low-frequency quasispecies. Results are interpreted against curated resistance databases such as Geno2pheno[HCV] and the HCV drug resistance advisory tables maintained by expert consortia.
Replicon-Based Phenotypic Assays
Patient-derived NS3, NS5A, or NS5B sequences are cloned into subgenomic replicon vectors and transiently transfected into Huh-7-derived hepatoma cells. Luciferase or fluorescence reporter activity is measured across serial drug dilutions to generate dose-response curves, from which EC50 values and fold-shifts versus reference are calculated.
Infectious Virus (HCVcc) Assays
For variants that require the complete viral life cycle, chimeric HCVcc constructs carrying patient-derived target genes are used to infect permissive cells. Infectivity is quantified by immunostaining or reporter readout under drug pressure, providing susceptibility data that reflects entry, replication, and assembly stages.
Pseudoparticle (HCVpp) Systems
HCV pseudoparticles expressing patient-derived envelope glycoproteins are employed when evaluating entry inhibitors or neutralizing antibody responses, complementing replication-focused DAA assays.
Quality Control and Validation
All assays incorporate certified reference strains, positive and negative controls, inter-run calibrators, and replicate testing. Assays are validated for linearity, limit of detection, precision, and robustness in accordance with CLSI guidelines and, where applicable, Good Laboratory Practice (GLP) standards.
Applications
- Guiding retreatment decisions in patients who have failed prior DAA therapy, particularly before prescribing salvage regimens such as sofosbuvir/velpatasvir/voxilaprevir.
- Pre-treatment baseline resistance evaluation for patients with advanced cirrhosis, genotype 3 infection, or other predictors of reduced response.
- Antiviral drug discovery programs, including high-throughput screening of NS3, NS5A, and NS5B inhibitor candidates and cross-resistance profiling.
- Clinical trial support, including subject stratification by resistance profile, monitoring of on-treatment viral breakthrough, and analysis of resistance emergence.
- Translational research into viral fitness, compensatory mutations, and the natural decay of resistant variants after drug withdrawal.
- Epidemiological surveillance of resistance-associated substitution prevalence across HCV genotypes and geographic regions.
FAQ
When is HCV drug susceptibility testing recommended?
Testing is most strongly recommended after failure of a DAA-containing regimen, before retreatment in patients with cirrhosis or genotype 3 infection, and in research settings studying antiviral resistance. Routine pre-treatment testing is generally not required given the high potency of current pan-genotypic regimens.
What sample volume and viral load are required?
Typically 1-2 mL of EDTA plasma with an HCV RNA level of at least 1,000 IU/mL is requested to ensure reliable amplification of all three target regions; lower viral loads may still yield partial results.
What is the difference between genotypic and phenotypic testing?
Genotypic testing identifies specific amino acid substitutions known to confer resistance, while phenotypic testing directly measures viral replication in the presence of drug concentrations and reports EC50 fold-changes. Phenotypic assays capture the combined effect of multiple or novel substitutions that databases cannot fully predict.
How long does testing take?
Genotypic sequencing typically requires 5-10 business days, whereas phenotypic replicon or HCVcc assays require approximately 2-4 weeks due to cloning, cell culture, and dose-response analysis steps.
Do resistance-associated substitutions persist after treatment ends?
Many NS5A RASs can persist for months to years, whereas NS3 and NS5B variants often decline more rapidly. Susceptibility testing can document whether resistant variants remain detectable before a retreatment course is initiated.
Can susceptibility testing predict treatment outcome?
It provides valuable risk stratification, but outcome depends on multiple factors including liver disease stage, viral genotype, regimen potency, and treatment duration. Results should always be interpreted together with the full clinical picture.